ArticleFrontiers in microbiology2022
Residues 318 and 323 in capsid protein are involved in immune circumvention of the atypical epizootic infection of infectious bursal disease virus.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An amino acid insertion in the PHI loop of the VP2 capsid protein of serotype 1 infectious bursal disease virus deeply modifies its antigenicity and abrogates its propagation into B cells.Veterinary research · 2026Article
- Infectious bursal disease virus suppresses humoral immunity via blocking antibody affinity maturation in chickens.iScience · 2026Article
- Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review.Viruses · 2026Article
- Enhancing MyD88 oligomerization is one important mechanism by which IBDV VP2 induces inflammatory response.PLoS pathogens · 2025Article
- Q221K mutation in VP2 drives antigenic shift of infectious bursal disease virus.Frontiers in immunology · 2025Article
- Novel Antigenic Variant Infectious Bursal Disease Virus Outbreaks in Japan from 2014 to 2023 and Characterization of an Isolate from Chicken.Pathogens (Basel, Switzerland) · 2024Article
- Molecular characterization of circulating infectious bursal disease viruses in chickens from different Egyptian governorates during 2023.Virology journal · 2024Article
- Infectious bursal disease virus affecting interferon regulatory factor 7 signaling through VP3 protein to facilitate viral replication.Frontiers in cellular and infection microbiology · 2024Article
- Comparative Pathogenicity of Three Strains of Infectious Bursal Disease Virus Closely Related to Poultry Industry.Viruses · 2023Article
- Genetic Insight into the Interaction of IBDV with Host-A Clue to the Development of Novel IBDV Vaccines.International journal of molecular sciences · 2023Review
- A Single Mutation of VP2 is Responsible for the Lethality and Antigenicity Differences between Novel Variant and Very Virulent IBDV Strains.Transboundary and emerging diseases · 2023Article
- Review
- Characterization and pathogenicity of a novel variant infectious bursal disease virus in China.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, atypical infectious bursal disease (IBD) caused by a novel variant infectious bursal disease virus (varIBDV) suddenly appeared in immunized chicken flocks in East Asia and led to serious economic losses. The epizootic varIBDV can partly circumvent the immune protection of the existing vaccines against the persistently circulating very virulent IBDV (vvIBDV), but its mechanism is still unknown. This study proved that the neutralizing titer of vvIBDV antiserum to the epizootic varIBDV reduced by 7.0 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.